Does hemodiafiltration improve the removal of homocysteine?

Stéphanie Badiou1, Marion Morena, Anne-Sophie Bargnoux

  • 1CHU Montpellier, Université Montpellier, Montpellier, France.

Hemodialysis International. International Symposium on Home Hemodialysis
|November 25, 2011
PubMed

Insights

Hemodiafiltration (HDF) significantly enhances homocysteine (Hcy) reduction in hemodialysis patients compared to standard hemodialysis (HD). This improved Hcy removal, linked to better middle molecule clearance, may help manage cardiovascular risk in dialysis patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Hyperhomocysteinemia is prevalent in hemodialysis patients, increasing cardiovascular risk.
  • Dialysis modality may influence homocysteine (Hcy) levels, independent of vitamin B status.

Purpose of the Study:

  • To compare the reduction rate (RR) of homocysteine (Hcy) and cysteine in patients undergoing standard hemodialysis (HD) versus hemodiafiltration (HDF).

Main Methods:

  • Seventy-five stable dialysis patients (35 HD, 40 HDF) were studied.
  • Biological parameters, including Hcy, cysteine, and beta2 microglobulin (β2m), were measured before and after a midweek dialysis session.
  • Dialysis efficacy markers like urea Kt/V and reduction ratios were assessed.

Main Results:

  • Hemodiafiltration (HDF) showed a significantly higher reduction rate for Hcy (46.0% vs. 41.5% in HD, P<0.05) and beta2 microglobulin (β2m) (78.6% vs. 72.0% in HD, P<0.001).
  • The reduction rate of cysteine was similar between HDF and HD.
  • Homocysteine (Hcy) reduction correlated positively with both urea Kt/V index and β2m reduction.

Conclusions:

  • Hemodiafiltration (HDF) offers superior homocysteine (Hcy) removal compared to standard hemodialysis (HD), even with similar dialysis efficacy (urea Kt/V).
  • Enhanced clearance of middle molecules like β2m in HDF may contribute to the improved Hcy reduction.
  • HDF may be a beneficial dialysis modality for managing hyperhomocysteinemia and associated cardiovascular risk in hemodialysis patients.

Related Concept Videos

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...